
References

- 1- **Barker WH, Mullooly JP, Getchell W (2006):** Changing incidence and survival for heart failure in a well-defined older population, *Circulation*; 113:799-805.
- 2- **Bateman DN (2004):** Digoxin-specific antibody fragments: how much and when? *Toxicol Rev*; 23:135-143.
- 3- **Beavo JA (1995):** Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. *Physiological Reviews*, 75: 725- 748.
- 4- **Blanc JJ, Bertault-Valls V, Fatemi M, et al., (2004):** Midterm benefits of left univentricular pacing in patients with congestive heart failure. *Circulation*; 109:1741-1744.
- 5- **Borgeson DD, Seward JB, Miller FA Jr et al., (1996) .** Frequency of Doppler measurable pulmonary artery pressures. *J Am Soc Echocardiography*; 9: 832–837. and reproducibility of biplane two-dimensional
- 6- **Bossone E, Duong-Wagner TH, Paciocco G, et al(1999):** Echocardiographic features of primary pulmonary hypertension. *J Am Soc Echocardiogr*; 12:655-662.
- 7- **Bossone E, Paciocco G, Iarussi D, et al (2002):** The prognostic role of the ECG in primary pulmonary hypertension. *Chest*;121:513-518.
- 8- **Braunwald E, Peter Lippy, Robert O. Bonow, et al. (2008):** ST Elevation myocardial infarction :diagnosis and management 50:1207-1300.
- 9- **Burnett A L (2005):** 5 mechanisms and therapeutic applications, *Am J Cardiol* **96**, pp. 29M–31M
- 10- **Butler J, Forman DE, Abraham WT, et al (2004):** Relationship between

heart failure treatment and development of worsening renal function among hospitalized patients. *Am Heart J*;147:331-338.

- 11- **Cheitlin MD, Hutter Jr AM, Brindis RG, et al (1999):** ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. *Journal of the American College of Cardiology*, 33: 273-282.
- 12- **Chockalingam A, Gnanavelu G, Venkatesan S, et al (2009)** and optimal dose of sildenafil in primary pulmonary hypertension. *Int J Cardiol*. Mar 10;99(1)91-5.
- 13- **Ciavarella SQ. (2003)** New insights into the treatment of pulmonary arterial hypertension. *Formulary*, mar;38(3);150-4,157-8,160.
- 14- **Cleland JG, Daubert JC, Erdmann E, et al (2005):** The effect of cardiac resynchronization on morbidity and mortality in heart failure. *N Engl J Med*; 352:1539 -1549.
- 15- **Cohn JN (1993):** Efficacy of vasodilators in the treatment of heart failure. *J Am Coll Cardiol*; 22:135A-138A.
- 16- **Cohn JN, Ferrari R, Sharpe N, et al (2000):** Cardiac remodeling concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. *J Am Coll Cardiol*; 35:569-582.
- 17- **Cohn JN, Johnson G, Ziesche S, et al (1991):** A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. *N Engl J Med*; 325:303-310.
- 18- **Cohn JN, Ziesche S, Smith R, et al (1997):** Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. *Vasodilator-*

- Heart Failure Trial (V-HeFT) Study Group. *Circulation*; 96:856-863.
- 19- **Dahlof B, Devereux RB, Kjeldsen SE, et al (2002):** Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. *Lancet*; 359:995-1003.
- 20- **De Bruyne LK (2003):** Mechanisms and management of diuretic resistance in congestive heart failure. *Postgrad Med J*;79:268-271.
- 21- **Dec GW (2003):** Digoxin remains useful in the management of chronic heart failure. *Med Clin North Am*;87:317-337.
- 22- **Degerman E, Belfrage P & Manganiello VC (1997):** Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). *Journal of Biological Chemistry*, 272: 6823-6826.
- 23- **Dell'Italia L, Sabri A (2004):** Activation of the renin-angiotensin system in hypertrophy and heart failure. In: Mann DL, ed. *Heart Failure: A Companion to Braunwald's Heart Disease*, Philadelphia: Saunders; :129-143.
- 24- **Deng MC, Edwards LB, Hertz MI, et al (2004):** Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: Second annual reportâ 2004. *J Heart Lung Transplant*;23:1027-1034.
- 25- **Dickstein K, Kjekshtus J (2002):** Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. *Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan*. *Lancet*;360:752-760.
- 26- **Drexler H, Hayoz D, Munzel T, et al (1992):** Endothelial function in chronic congestive heart failure. *Am J Cardiol*;69:1596-1601.

- 27- **Eisenhofer G, Friberg P, Rundqvist B, et al (1996):** Cardiac sympathetic nerve function in congestive heart failure. *Circulation*;93:1667-1676.
- 28- **Elkayam U (1996):** Prevention of nitrate tolerance with concomitant administration of hydralazine. *Can J Cardiol*;12(suppl C):17C-21C.
- 29- **Eriksson H, Cowie MR, Mosterd A, et al., (1997):** The epidemiology of heart failure. *Eur Heart J*;18:208-225.
- 30- **Francis GS, Pierpont GL. (1988):** Pathophysiology of congestive heart failure secondary to congestive and ischemic cardiomyopathy. In: Shaver JA, ed. *Cardiomyopathies: Clinical Presentation, Differential Diagnosis, and Management*. Philadelphia, Pa: FA Davis; 1988:57–74.
- 31- **G.D. Lewis, J. Lachmann, J. Camuso, J.J. Lepore, J. Shin and M.E. Martinovic et al., (2007)** Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure, *Circulation* 115, pp. 59–66.
- 32- **Galie N. , Ghofrani H.A. , Torbicki A. , et al., (2005)** Sildenafil citrate therapy for pulmonary arterial hypertension (for the Sildenafil Use in Pulmonary Arterial Hypertension “SUPER” Study Group), *N Engl J Med* 353, pp. 2148–2157
- 33- **Geelen P, Drolet B, Rail J, et al., (2000):** Sildenafil (Viagra) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current. *Circulation*, 102: 275-277.
- 34- **Gilligan DM, Panza JA, Kilcoyne CM, et al (1994):** Contribution of endothelium-derived nitric oxide to exercise-induced vasodilation. *Circulation*;90:2853-2858.
- 35- **Givertz M, Colucci WS, Braunwald E. (2005):** Clinical aspects of heart failure: High-output failure, pulmonary edema. In *Braunwald's Heart Disease*, 7th ed. Philadelphia: Elsevier; 539-568.

- 36- **Goldsmith SR, Francis GS, Cowley AW, et al (1993):** Increased plasma arginine vasopressin levels in patients with congestive heart failure. *J Am Coll Cardiol*;1:1385-1390.
- 37- **Goldstein I, Lue TF, Padma-Nathan H, et al (1998):** Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. *New England Journal of Medicine*, 338: 1397-1404
- 38- **Gottdiener JS, McClelland RL, Marshall R, et al.(2002):** Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. *Ann Intern Med* 2; 137:631-639.
- 39- **Gregoratos G, Abrams J, Epstein AE, et al.(2002):** ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/NASPE Committee to Update the 1998 Pacemaker Guidelines). *Circulation*; 106:2145-2161.
- 40- **Gruenwald I (2003):** Effects of sildenafil citrate (Viagra) on hemodynamic parameters during exercise testing and occurrence of ventricular arrhythmias in patients with erectile dysfunction and cardiovascular disease. *European Urology*, 43: 544-551.
- 41- **Guazzi AJ, Chiao TB, Tsang MP, et al. (2009): sildenafil for pulmonary hypertension , Ann pharmacother. May: 39 (5): 869-84.**
- 42- **Gullestad L. , Manhenke C. , Aarsland T. , et al., (2001)** Effect of metoprolol CR/XL on exercise tolerance in chronic heart failure-substudy to the MERIT-HF trial, *Eur J Heart Fail* 3, pp. 463–468.
- 43- **Halcox J.P.J. , Nour K.R.A. , Zalos G. , et al., (2002)** The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia, *J Am Coll Cardiol* 40, pp. 1232–1240

- 44- **Haulica I, Petrescu G, Slatineanu SM, et al (2004):** New bioactive angiotensins formation pathways and functional involvements. Rom J Intern Med; 42:27.
- 45- **Herrmann HC, Chang G, Klugherz BD & Mahoney PD (2000):** Hemodynamic effects of sildenafil in men with severe coronary artery disease. New England Journal of Medicine, 342: 1622-1626.
- 46- **Hickey M, Fraser IS (1995):** Nitric oxide production and heart failure (letter). Lancet;345:390-391.
- 47- **Hitinder S. Gurm, Patrick L, Whitlow, et al. (2009):** The impact of body mass index on short- and long-term outcomes inpatients. J Am Coll Cardiol; 39:834-840.
- 48- **Ho KKL, Pinsky JL, Kannel WB, et al (1993) :** The epidemiology of heart failure: the Framingham study. J Am Coll Cardiol;22(suppl A):6A-13A.
- 49- **Humbert M,simonneau G, stibon O,et al (2008).**primary pulmonary hypertension; current therapy. Prog cardiovasc Dis;45;115-28.
- 50- **Jackson G,Benjamin N, Jackson N,et al. (2008)**effects of sildenafil citrate on human hemodynamics .Am J Cardiol.;83;13c-20c
- 51- **Jiang JP, Downing SE (1990):** Catecholamine cardiomyopathy: review and analysis of pathogenetic mechanisms. Yale J Biol Med;63:581-591.
- 52- **Johnson W, Omland T, Hall C, et al (2002):** Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J Am Coll Cardiol;39:1623-1629.
- 53- **Jong P, Vowinckel E, Liu P, et al.(2002):** Prognosis and determinants of survival in patients newly hospitalized for heart failure. Arch Intern Med; 162:1689-1694.
- 54- **Kannel WB, Belanger AJ.(1991):** Epidemiology of heart failure. Am

Heart J.;121:951–957.

- 55- **Karatza AA, Bush A, Magee AG. (2005)** safety and efficacy of sildenafil therapy in children with pulmonary hypertension. *Int J Cardiol.* Apr 20; 100 (2);267-73
- 56- **Kataoka M, Satoh T, manabe T, Anzai T. (2005)** oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. *Circ J.* Apr;69(4);989-92.
- 57- **Katz S.D. , Balidemaj K. , Homma S. , et al 2000)** Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure, *J Am Coll Cardiol* **36**, pp. 845–851
- 58- **Katz S.D. , Hryniewicz K. , Hriljac I. , et al., (2005)** Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure, *Circulation* **111**, pp. 310–314
- 59- **Kaya D, Guler C, Esen AM, Barutcu I & Dincel C (2004):** Sildenafil citrate does not alter ventricular repolarization properties: novel evidence from dynamic QT analysis. *Annals of Noninvasive Electrocardiology*, 9: 228-233.
- 60- **Kim CB, Braunwald E (1993):** Potential benefits of late reperfusion of infarcted myocardium. *Circulation*;88:2426-2436.
- 61- **Kip KE, Marroquin OC, Kelley DE, et al. (2004):** Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: a report from the Women's Ischemia Syndrome Evaluation (WISE) study. *Circulation*; 09:706-7 13.
- 62- **Kitsis RN, Scheuer J (1996):** Functional significance of alterations in cardiac contractile protein isoforms. *Clin Cardiol*;19:9-18.
- 63- **Koelling TM, Chen RS, Lubwama RN, et al (2004):** The expanding

national burden of heart failure in the United States: the influence of heart failure in women. *Am Heart J*;147:74 –78.

- 64- **Kostis JB, Shelton B, Gosselin G, et al (1996):** Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD): SOLVD Investigators. *Am Heart J*;131:350-355.
- 65- **Kothari SS & Duggal B (2008).** Chronic oral sildenafil therapy in severe pulmonary artery hypertension. *Indian Heart Journal*, 54: 404-409.
- 66- **Lamas GA, Flaker GC, Mitchell G, et al., (1995):** Effect of infarct artery patency on prognosis after acute myocardial infarction. *Circulation*;92:1101-1109.
- 67- **Lee AJ,Chiao TB,Tsang Mp. (2005);** sildenafil for pulmonary hypertension. *Ann pharmacother.* May;39(5);869-84.
- 68- **Lee DS, Austin PC, Rouleau JL, et al.(2008):** Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. *JAMA* 2003; 290:2581-2587.
- 69- **Leuchte HH,et al. (2004)** Hemodynamic response to sildenafil,nitric oxide,and iloprost in primary pulmonary hypertension.*chest.* Feb;125(2);580-6.
- 70- **Levy D, Kenchiah, S, Larson MG, et al.(2002):** Long-term trends in the incidence of and survival with heart failure. *N Engl J Med* 2; 347:1397-1402.
- 71- **Levy D, Larson MG, Vasan RS, et al (1996):** The progression from hypertension to congestive heart failure. *JAMA*;275:1557-1562.
- 72- **Lewis G D, Shah R, Shahzad K, et al., (2007)** Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension, *Circulation* 116, pp. 1555–1562.
- 73- **Lloyd-Jones DM, Larson MG, Leip EP, et al.(2002):** Lifetime risk for

- developing congestive heart failure: the Framingham Heart Study. *Circulation*; 106:3068-3072.
- 74- **Mahon NG, Blackstone EH, Francis GS, et al.(2002):** The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. *J Am Coll Cardiol*;40:1106-1113.
- 75- **Maisel A (2001):** B-type natriuretic peptide levels: a potential novel “white count” for congestive heart failure. *J Card Fail.*; 7:183–193.
- 76- **Mancini D M and Lang C C, (2004)** Alterations in pulmonary and diaphragmatic function in heart failure. In: D.L. Man, Editor, *Heart failure: a companion to Braunwald's heart disease* (1st ed.), Saunders, Philadelphia, pp. 304–305
- 77- **Mann DL, Kent RL, Parsons B, et al (1992):** Adrenergic effects of the biology of the adult mammalian cardiocyte. *Circulation*;85:790-804.
- 78- **Mansour M, Reddy VY, Singh J, et al (2005):** Three-dimensional reconstruction of the coronary sinus using rotational angiography. *J Cardiovasc Electrophysiol*;16:675-676.
- 79- **Marroquin OC, Kip KE, Kelley DE, et al. (2004):** Women’s Ischemia Syndrome Evaluation Investigators. Metabolic syndrome modifies the cardiovascular risk. a report from the Women’s Ischemia Syndrome Evaluation. *Circulation*; 109:714 - 21.
- 80- **Masoudi FA, Havranek EP, Krumholz HM (2002):** The burden of chronic congestive heart failure in older persons: magnitude and implications for policy and research. *Heart Fail Rev.*;7:9 –16.
- 81- **McAlister FA, Ezekowitz JA, Wiebe N, et al (2004):** Systematic review: cardiac resynchronization in patients with symptomatic heart failure. *Ann Intern Med*;141:381-390.

- 82- **McGoon M, Gutterman D, Steen V, et al (2004):** Screening, early detection, and diagnosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. *Chest*;126:14S-34S.
- 83- **McKelvie RS, Yusuf S, Pericak D, et al (1999):** Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. *Circulation*; 100:1056-1064.
- 84- **McKelvie RS, Yusuf S, Pericak D, et al., (1999):** Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. The RESOLVD Pilot Study Investigators. *Circulation*;100:1056-1064.
- 85- **McMurray JJ, Pfeffer MA. Heart failure. Lancet 2005; 365:** 1877–1889.
- 86- **McMurray JJ, Stewart S. 2002:** Epidemiology, aetiology, and prognosis of heart failure. *Heart*; 83:596-602.
- 87- **Mehra MR, Uber PA, Park MH, et al (2004):** Obesity and suppressed B-type natriuretic peptide levels in heart failure. *J Am Coll Cardiol.*;43: 1590–1595.
- 88- **MehtaS,sildenafil ; (2003)** for pulmonary arterial hypertension; exciting,but protection required.*Chest Apr*;123(4);989-92
- 89- **MERIT-HF Study Group (1999):** Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT HF). *Lancet*;353:2001-2007.milrinone on mortality in severe chronic heart failure. *The Promise*
- 90- **Moraes D L, Colucci W S and Givertz M M, (2000)** Secondary

- pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management, *Circulation* **102**, pp. 1718–1723
- 91- **Morgan K P, A Kapur and K J Beatt, et al. (2004):** Anatomy of coronary disease in diabetic patients. *Heart*; 90:732-738.
- 92- **Moss AJ, Brown MW, Cannom DS, et al (2005):** Multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT): Design and clinical protocol. *Ann Noninvas Electrocardiol*; 10(suppl):34-43.
- 93- **Naunyn B (2003):** *Der Diabetes Mellitus*. 2nd ed. Vienna: Holder, 1906:260.
- 94- **Nazzareno Galie,Hosseini A, (2009)** Ghofrani,Adam Torbicki. safety and efficacy of sildenafil therapy in children with pulmonary hypertension. *Int J Cardiol*. Apr 20; 100 (2);267-73
- 95- **Nelson GS, Berger RD, Fetics BJ, et al., (2000):** Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. *Circulation*;102:3053-3059.
- 96- **O'Connell JB, Bristow MR. (1994): Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant. ;13:S107–S112.**
- 97- **Otterstad JE, Froeland G, Sutton STM, et al (1997):** Accuracy and reproducibility of biplane two-dimensional echocardiographic measurements of left ventricular dimensions and function. *Eur Heart J*; 18: 507–513. P.1223
- 98- **Packer M (1996):** Do angiotensin-converting enzyme inhibitors prolong life in patients with heart failure treated in clinical practice? *J Am Coll*

Cardiol;28:1323-1327

- 99- Pfeffer MA, Braunwald E (1990):** Ventricular remodeling after myocardial infarction. *Circulation*;81:1161-1172.
- 100- Pfeffer MA, McMurray JJ, Velazquez EJ, et al (2003):** Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. *N Engl J Med*;349:1893-1906.
- 101- Pfeffer MA, Swedberg K, Granger CB, et al (2003):** Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. *Lancet*;362:759-766.
- 102- Pitt B, Poole-Wilson PA, Segal R, et al (2000):** Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. *Lancet*;355:1582-1587.
- 103- Pitt B, Remme W, Zannad F (2003):** Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. *N Engl J Med* ; 348:1309.
- 104- Pitt B, Zannad F, Remme WJ, et al (1999):** The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. *N Engl J Med* ; 341:709. problem. *J Intern Med* 1995;237:135-14
- 105- Rathore SS, Wang Y, Krumholz HM (2002):** Sex-based differences in the effect of digoxin for the treatment of heart failure. *N Engl J Med*;347:1403-1411.
- 106- Rector RS, Bank AJ, Mullen KA, et al (1996):** Randomized, double-blind, placebo-controlled study of supplemental oral Larginine in patients with heart failure. *Circulation*;93:2135-2141.
- 107- Redfield MM, Jacobsen SJ, Burnett JC, et al.(2003):** Burden of systolic

and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. *JAMA* 3;289:194-202.

108- Renlund DG (2004): Building a bridge to heart transplantation. *N Engl J Med*;351:849-851.

109- Rich S, Dantzker DR, Ayres SM et al., (2004) : Primary pulmonary hypertension. A national prospective study. *Ann Intern*

110- Richards AM. (2004) : Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. *Lancet*. 2000; 355:1126 –1130.

111- Rodeheffer RJ, Lerman A, Heublein D, et al (1992): Increased plasma concentrations of endothelin in congestive heart failure in humans. *Mayo Clin Proc*;67:719-724.

112- Sastry BK. (2007) Clinical efficacy of sildenafil in primary pulmonary hypertension;a randomized, placebo-controlled,double-blind,crossover study. *J AmColl cardiol*, Apr;43(7),pp.1149-53.

113- Schrier RW, Abraham WT (1999) : Hormones and hemodynamics in heart failure. *N Engl J Med* ; 341:577.

114- Schwinger RHG, Bohm M, Koch A, et al (1994): The failing human heart is unable to use the Frank-Starling mechanism. *Circ Res*;74:959-969.

115- Shakir SA, Wilton LV, Boshier A, Layton D & Heeley E (2001): Cardiovascular events in users of sildenafil: results from first phase of prescription event monitoring in England. *British Medical Journal*,

116- Smith WM. (2000): Epidemiology of congestive heart failure. *Am J Cardiol*;55(suppl A):3A-8A.

117- St. John Sutton MG, Sharpe N (2000): Left ventricular remodeling after myocardial infarction. *Circulation*;101:2981-2988.

- 118- Stewart S.(2003):** Prognosis of patients with heart failure compared with common types of cancer. *Heart Fail Monitor*;3;87-94.
- 119- Stibon O, simonneau G,Humbert M.** primary pulmonary hypertension; current therapy. *Prog cardiovasc Dis* 2008;45;115-28.
- 120- Stone GW, Ohman EM, Miller MF, et al., (2003):** on temporary utilization and outcomes of intra-aortic balloon counter pulsation in acute myocardial infarction. *J Am Coll Cardiol* ; 41:1940.
- 121- Strickberger SA, Conti J, Daoud EG, et al (2005):** Patient selection for cardiac resynchronization therapy: from the Council on Clinical Cardiology Subcommittee on Electrocardiography and Arrhythmias and the Quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. *Circulation*;111:2146-2150.
- 122- Struthers AD (2004):** The clinical implications of aldosterone escape in congestive heart failure. *Eur J Heart Fail*;6:539-545.
- 123- Tamirisa KP, Aaronson KD, Koelling TM (2004):** Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. *Am Heart J*;148:971-978.
- 124- Tang WH, Francis GS (2003):** Trends and treatment of heart failure developing after acute myocardial infarction. *Am Heart Hosp J*;1:216-218.
- 125- Tang WHW, Francis GS (2003):** Natural history of heart failure. In: Kukin M, Fuster V, eds. *Oxidative stress and heart failure*. Armonk, NY: Futura,;3-47.
- 126- Taylor DO, Edwards LB, Boucek MM, et al.,(2004):** The Registry of the International Society for Heart and Lung Transplantation: Twenty-first official adult heart transplant report 2004. *J Heart Lung Transplant*

2004;23:796-803.

- 127- Topol EJ, Robert M. Califf, et al. (2007):** Acute myocardial Infarction, early diagnosis and management 19:280-302.
- 128- Topol EJ, Robert M. Califf, et al. (2007): chronic Heart Failure Management.** 87;1377-1378 87;1385-1386
- 129- Topol EJ, Robert M. Califf, et al. (2007): Pathophysiology of Heart failure** 85; 1340-1342
- 130- Vanderheyden M, Goethals M, Verstreken S, et al (2004):** Wall stress modulates brain natriuretic peptide production in pressure overload cardiomyopathy. J Am Coll Cardiol;44:2349-2354.
- 131- Wei C-M, Heublein DM, Perrella MA, et al (1993):** Natriuretic peptide system in human heart failure. Circulation;88:1004-1009.
- 132- Weinfeld MS, Chertow GM, Stevenson LW.(1999):** Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J.;138:285–290.
- 133- Weisman HF, Bush DE, Mannisi JA, et al (1988):** Cellular mechanisms of myocardial infarct expansion. Circulation;78:186-201.
- 134- Wong RC, Koh GM, Choong PH, Yip WL (2006).** Oral sildenafil therapy improves health-related quality of life and functional status in pulmonary arterial hypertension. Int J Cardiol. Oct 23;
- 135- Young JB (1994):** Do digitalis glycosides still have a role in congestive heart failure? Cardiol Clin; 12:51-61.